Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6129506rdf:typepubmed:Citationlld:pubmed
pubmed-article:6129506lifeskim:mentionsumls-concept:C0023452lld:lifeskim
pubmed-article:6129506lifeskim:mentionsumls-concept:C1285572lld:lifeskim
pubmed-article:6129506lifeskim:mentionsumls-concept:C1314763lld:lifeskim
pubmed-article:6129506lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:6129506pubmed:issue8313lld:pubmed
pubmed-article:6129506pubmed:dateCreated1983-2-14lld:pubmed
pubmed-article:6129506pubmed:abstractTextLymphoblasts from 59 children with non-T, non-B acute lymphoblastic leukaemia were studied with monoclonal antibodies to four cell-surface proteins. 87% of the children had lymphoblasts positive for HLA-DR, 82% for p30, 75% for p24, and 72% for CALLA. The commonest composite phenotype was HLA-DR+ p30+ CALLA+ p24+. Significant correlations were seen between expression of HLA-DR, p30, and CALLA, but not p24. p30- and CALLA phenotypes were found in patients with high white-blood-cell counts (WBC) and splenomegaly. With standard chemotherapy, disease-free survival from time of remission was shorter in p30- and CALLA- patients than in others. Splenomegaly was associated with poor disease-free survival and provided prognostic information independent of phenotype. High WBC was less significant than phenotype in predicting outcome and was not independent of phenotype.lld:pubmed
pubmed-article:6129506pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6129506pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6129506pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6129506pubmed:languageenglld:pubmed
pubmed-article:6129506pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6129506pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6129506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6129506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6129506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6129506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6129506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6129506pubmed:statusMEDLINElld:pubmed
pubmed-article:6129506pubmed:monthDeclld:pubmed
pubmed-article:6129506pubmed:issn0140-6736lld:pubmed
pubmed-article:6129506pubmed:authorpubmed-author:KerseyJJlld:pubmed
pubmed-article:6129506pubmed:authorpubmed-author:GoldmanAAlld:pubmed
pubmed-article:6129506pubmed:authorpubmed-author:Gajl-Peczalsk...lld:pubmed
pubmed-article:6129506pubmed:authorpubmed-author:LeBienTTlld:pubmed
pubmed-article:6129506pubmed:authorpubmed-author:NesbitMMlld:pubmed
pubmed-article:6129506pubmed:authorpubmed-author:PerryGGlld:pubmed
pubmed-article:6129506pubmed:authorpubmed-author:AbramsonCClld:pubmed
pubmed-article:6129506pubmed:issnTypePrintlld:pubmed
pubmed-article:6129506pubmed:day25lld:pubmed
pubmed-article:6129506pubmed:volume2lld:pubmed
pubmed-article:6129506pubmed:ownerNLMlld:pubmed
pubmed-article:6129506pubmed:authorsCompleteYlld:pubmed
pubmed-article:6129506pubmed:pagination1419-23lld:pubmed
pubmed-article:6129506pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:6129506pubmed:meshHeadingpubmed-meshheading:6129506-...lld:pubmed
pubmed-article:6129506pubmed:meshHeadingpubmed-meshheading:6129506-...lld:pubmed
pubmed-article:6129506pubmed:meshHeadingpubmed-meshheading:6129506-...lld:pubmed
pubmed-article:6129506pubmed:meshHeadingpubmed-meshheading:6129506-...lld:pubmed
pubmed-article:6129506pubmed:meshHeadingpubmed-meshheading:6129506-...lld:pubmed
pubmed-article:6129506pubmed:meshHeadingpubmed-meshheading:6129506-...lld:pubmed
pubmed-article:6129506pubmed:meshHeadingpubmed-meshheading:6129506-...lld:pubmed
pubmed-article:6129506pubmed:meshHeadingpubmed-meshheading:6129506-...lld:pubmed
pubmed-article:6129506pubmed:meshHeadingpubmed-meshheading:6129506-...lld:pubmed
pubmed-article:6129506pubmed:meshHeadingpubmed-meshheading:6129506-...lld:pubmed
pubmed-article:6129506pubmed:meshHeadingpubmed-meshheading:6129506-...lld:pubmed
pubmed-article:6129506pubmed:meshHeadingpubmed-meshheading:6129506-...lld:pubmed
pubmed-article:6129506pubmed:meshHeadingpubmed-meshheading:6129506-...lld:pubmed
pubmed-article:6129506pubmed:meshHeadingpubmed-meshheading:6129506-...lld:pubmed
pubmed-article:6129506pubmed:meshHeadingpubmed-meshheading:6129506-...lld:pubmed
pubmed-article:6129506pubmed:meshHeadingpubmed-meshheading:6129506-...lld:pubmed
pubmed-article:6129506pubmed:meshHeadingpubmed-meshheading:6129506-...lld:pubmed
pubmed-article:6129506pubmed:year1982lld:pubmed
pubmed-article:6129506pubmed:articleTitleClinical usefulness of monoclonal-antibody phenotyping in childhood acute lymphoblastic leukemia.lld:pubmed
pubmed-article:6129506pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6129506pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6129506lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6129506lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6129506lld:pubmed